MedPath

Orphenadrine Citrate

ORPHENADRINE CITRATE INJECTION, USP Rx Only

Approved
Approval ID

aec8ad3a-f717-4e74-b7b9-19debdaad79a

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 20, 2016

Manufacturers
FDA

Actavis Pharma, Inc.

DUNS: 119723554

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Orphenadrine Citrate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0591-3222
Application NumberANDA084779
Product Classification
M
Marketing Category
C73584
G
Generic Name
Orphenadrine Citrate
Product Specifications
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateNovember 29, 2018
FDA Product Classification

INGREDIENTS (6)

WATERInactive
Code: 059QF0KO0R
Classification: IACT
ORPHENADRINE CITRATEActive
Quantity: 30 mg in 1 mL
Code: X0A40N8I4S
Classification: ACTIB
SODIUM METABISULFITEInactive
Quantity: 0.91 mg in 1 mL
Code: 4VON5FNS3C
Classification: IACT
SODIUM CHLORIDEInactive
Quantity: 2.9 mg in 1 mL
Code: 451W47IQ8X
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Orphenadrine Citrate - FDA Drug Approval Details